Vertex Pharma Reports Selected Triple Combo Of Next-Gen Corrector VX-445, Tezacaftor, Ivacaftor To Submit For Potential Global Regulatory Approvals For Peoples Ages 12+ With Cystic Fibrosis
Benzinga Newsdesk